2-(2,6-Dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde

Catalog No. :
ACFRAG311
CAS No. :
2866307-09-5
Molecular Formula :
C14H12N2O4
Molecular Weight :
272.26

IUPAC Name:2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde

2-(2,6-Dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$188.00Login to see priceIn stockInquiry
100mg98%$313.00Login to see priceIn stockInquiry
250mg98%$562.00Login to see priceIn stockInquiry
1g98%$1138.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2,6-Dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde
IUPAC Name2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde
Molecular FormulaC14H12N2O4
Molecular Weight272.26
SMILESO=CC1=CC2=C(CN(C(CC3)C(NC3=O)=O)C2=O)C=C1
InChI KeyMVHIDMVASPCRTH-UHFFFAOYSA-N
Synonym1H-Isoindole-5-carboxaldehyde, 2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-3-oxo-;2-(2,6-Dioxopiperidin-3-yl)-3-oxoisoindoline-5-carbaldehyde;2-(2,6-dioxo-3-piperidyl)-3-oxo-isoindoline-5-carbaldehyde
CAS No.2866307-09-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACFRAG311 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFRAG311 route product structure diagram
    ACFRAG3112866307-09-5 In Stock
Inquiry

2. ACFRAG311 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEGKF645 route compound structure diagram
    ACEGKF6452803882-16-6 In Stock
  2. Then
  3. ACFRAG311 route product structure diagram
    ACFRAG3112866307-09-5 In Stock
Inquiry

Comments (0)